A population-based European cohort study of persistence in newly diagnosed hypertensive patients

Journal of Human Hypertension

Volumn 16, Issue 8, 2002, Pages 569-575

  Hasford, Joerg ^a   Mimran, A ^b   Simons, W R ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c Global Health Economics and Outcomes Research Bayer HealthCare   (United States)

Author keywords

Angiotensin II receptor antagonist (AIIRA); Antihypertensive drugs; Irbesartan; Losartan; Monotherapy; Persistence

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; IRBESARTAN; LOSARTAN; VALSARTAN;

ADULT; AGED; ANAMNESIS; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG TOLERABILITY; EUROPE; EVALUATION; FEMALE; FOLLOW UP; FRANCE; GENERAL PRACTITIONER; GERMANY; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD; MONOTHERAPY; OUTCOMES RESEARCH; PATIENT SATISFACTION; POPULATION RESEARCH; PRESCRIPTION; SCORING SYSTEM; STROKE; UNITED KINGDOM;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; EUROPE; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RETREATMENT; TETRAZOLES; TREATMENT FAILURE;

EID: 0036672238     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001451     Document Type: Article

References (39)

1. Prevalence, awareness, treatment and control of hypertension in a population over the age of 65 years: Results from the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY)
2. Prevalence, treatment, and control of hypertension in the French population: Data from a survey on high blood pressure in general practice, 1994
3. Awareness, treatment, and control of hypertension in Canada
4. Prevalence and control of arterial hypertension in the south-east of Spain: A radical but still insufficient improvement
5. Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991
6. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease
7. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
8. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
9. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
10. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
11. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
12. Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid?
13. Blood pressure screening, management and control in England: Results from the health survey for England 1994
14. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population
15. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure
16. Continuation of initial antihypertensive medication after 1 year of therapy
17. A randomized, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension
18. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension
19. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension
20. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine
21. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension
22. ACE inhibitor-versus angiotensin II blocker-induced cough and angioedema
23. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension
24. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan
25. Characteristics of practices contributing to the MediPlus database and the implications for its use in epidemiological research
26. Data Safety and Drug Safety in Germany: A closing gap?
27. Use of mediplus patient database in healthcare research
28. Irbesartan results in superior blood pressure reduction vs valsartan
29. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension
30. Variations in compliance among hypertensive patients by drug class: Implications for health care costs
31. Performance of generalized estimating equations in practical situations
32. How well is hypertension controlled in Europe?
33. Persistence with treatment for hypertension in actual practice
34. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data
35. Persistency with angiotensin receptor blockers (ARB) versus other antihypertensives (AHT) using the Saskatchewan database
36. Time to patient discontinuation of antihypertensive drugs in different classes
37. Changes in antihypertensive therapy - The role of adverse effects and compliance
38. Use and adverse reactions of antihypertensive drugs in Spain
39. Adverse clinical sequelae after dropping out of a tertiary hypertension clinic